白云山完成广药创投基金备案

财中社
07 Jan

  财中社1月7日电白云山(600332/00874)发布关于完成私募基金备案暨关联交易进展的公告。公告中提到,公司同意广药基金投资不超过6.9亿元认购广药创投基金的有限合伙份额,并已于2024年9月9日完成工商登记,首期出资合计4亿元。

  此外,广药创投基金于2025年1月6日在中国证券投资基金业协会完成备案,备案信息包括基金名称为“广州广药产投创业投资基金合伙企业(有限合伙)”,管理人为广州广药资本私募基金管理有限公司,托管人为招商银行股份有限公司,备案编号为SAPH93。

  2024年前三季度,白云山实现收入590.6亿元,归母净利润31.59亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10